

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization's database

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Bonaldo G., Vaccheri A., Melis M., Motola D. (2020). Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization's database. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 50(4), 763-771 [10.1007/s11239-020-02147-y].

Availability:

This version is available at: <https://hdl.handle.net/11585/796115> since: 2021-02-08

Published:

DOI: <http://doi.org/10.1007/s11239-020-02147-y>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

This is the final peer-reviewed accepted manuscript of:

Bonaldo, G., Vaccheri, A., Melis, M. *et al.* Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization's database. *J Thromb Thrombolysis* 50, 763–771 (2020).

The final published version is available online at:

<https://doi.org/10.1007/s11239-020-02147-y>

Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)

When citing, please refer to the published version.

Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization's database
Running head: Drug-induced intravascular coagulation

Authors:

Giulia Bonaldo PharmD, Alberto Vaccheri PhD, Mauro Melis PharmD, Domenico Motola PhD

Unit of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, via Irnerio 48, 40126, Bologna, Italy; Telephone: 0512091781

Corresponding author:

Dr Giulia Bonaldo, Department of Medical and Surgical Sciences, University of Bologna,
via Irnerio 48, 40126, Bologna, Italy. ORCID: <https://orcid.org/0000-0002-3302-1460>

E-mail: giulia.bonaldo2@unibo.it

Abstract word count: 202

Manuscript word count: 2364

Number of references: 14

Number of figures and tables: 1 figure, 2 tables

Number of supplemental illustrations/tables: none

Acknowledgments

We are grateful to the Uppsala Monitoring Centre—WHO Collaborating Centre for International Drug Monitoring for providing data. The information comes from a variety of sources, and the likelihood that the suspected adverse reaction is drug-related is not the same in all cases. The information does not represent the opinion of the World Health Organization. We would like to thank Mauro Venegoni, MD, for his authoritative and helpful comments to the manuscript and Laura Rossi, PharmD, who participated in this research when preparing her graduation thesis at the Unit of Pharmacology, University of Bologna.

Abstract.

Background: Disseminated intravascular coagulation (DIC) occurs in several clinical conditions, including drug therapy. We aim to investigate the association between several drug classes use and DIC onset, using the reports of Adverse Drug Reactions (ADR) collected in Vigibase, the World Health Organization database of ADR.

Methods: We collected reports of drug-related DIC from 1968 to September 2015 and classified in VigiBase according to the MedDRA (Medical Dictionary for Regulatory Activities) term “Disseminated intravascular coagulation”. A disproportionality analysis using Reporting Odds Ratio (ROR) was performed.

Results: Overall 4653 reports of drug-associated DIC were selected, 75.9% was serious. DIC was significantly ($ROR > 1$) associated with 88 drugs, mainly antineoplastic agents, antithrombotic agents and antibacterials for systemic use. Among of the most frequently reported individual drugs were dabigatran (94 reports) $ROR = 1.34$ ($1.08 - 1.67$), oxaliplatin and bevacizumab both with 75 reports and $ROR = 1.77$ ($1.38 - 2.27$) and 2.02 ($1.57 - 2.61$), respectively.

Conclusion: A considerable number of drugs widely used in the population may be associated with the potential occurrence of DIC. For many of these, the ADR is not listed. The high number of drugs involved underline the importance of evaluate this condition such as an ADR that might occur during therapy.

Keywords: Adverse Drug Reactions, Disseminated Intravascular Coagulation, Drug Safety, Pharmacovigilance.

23 **Keypoints**

- 24 1. The evaluation of possible drug-induced serious syndromes is important to
25 guarantee the patients' safety.
- 26 2. A high number of drugs widely used in the population may be associated with
27 rare and serious adverse drug reactions.
- 28 3. Clinicians should be aware of the importance to identify and report every case of
29 suspected drug – related disseminated intravascular coagulation.
- 30 4. The assessment of the association between the drug and the adverse drug
31 reaction may result in the updating of the summary of product characteristics.
- 32 5. Early detection of possible drug-induced disseminated intravascular coagulation
33 makes management easier by the possible suspension of the suspect drug.

34

Introduction

Blood coagulation is a physiological process put in place by the body during particular conditions; blood has to preserve its fluidity within vascular system but at the same time should be able to coagulate when exposed to non – endothelial surface in vascular lesion site and also to reset its normal flow after coagulation, through fibrinolysis [1]. Dysregulation of the homeostatic pathways results in changes that may affect preponderance of fibrinolysis or blood coagulation. Disseminated intravascular coagulation consists in the co-occurrence of both these components. Half a century ago, disseminated intravascular coagulation wasn't known and during autopsy it was almost impossible to find evidence of vascular disorders. Only at the end of the 1970s, more was known about it and, in addition, Sparo and colleagues [2] defined the acronym DIC as “Death Is Coming”, underlying the impact that this condition has on patients' life. DIC is a rare and serious syndrome characterized by the wide activation of coagulation process resulting in fibrin formation and consequent thrombosis of small to medium vessels [3]. At the same time, depletion of coagulation proteins and platelets brings to severe bleeding. Recent studies clarified the pathogenetic pathway of the syndrome that seems to be caused by activation of pro inflammatory cytokines, that along with suppression of anticoagulation pathway, culminate to generation of thrombin. This activation takes place from interleukin-6 (IL-6) and, indirectly, from tumor necrosis factor alfa through its influences in IL-6 activation [4]. DIC may result as a complication of serious infection such as sepsis, severe trauma, vascular disorders, obstetrical complications, toxins or cancer. Last but not least, DIC could be also considered as an adverse drug reaction (ADR) although in literature there are very few evidences in this regard [5,6]. To the best of our knowledge, no previous studies have analyzed reports of ADRs related to DIC deriving from spontaneous reporting system.

We aimed to investigate the potential association gathered from the use of several drug classes and the onset of DIC in order to improve the knowledge about DIC as an ADR and to underline the drugs for which it should be considered. By analyzing WHO database of adverse drug reactions and through evaluation of international literature, we want to give an overview of a subject about which little is known to date.

Methods

This is a case-by-case evaluation of all the reports of disseminated intravascular coagulation reported in the Vigibase, the WHO Global Individual Case Safety Report (ICSR) database at the Uppsala Monitoring Centre. The center has received reports about individual suspected ADRs from the countries participating in the WHO Programme for International Drug Monitoring (PIDM) starting from 1968 [7]. We collected all the suspected DIC-related cases reported from 1968 to September 2015 and classified in Vigibase with the MedDRA (Medical Dictionary for Regulatory Activities) Preferred term level “disseminated intravascular coagulation” and “disseminated intravascular coagulation in newborn”. The MedDRA is a standardized medical terminology used worldwide and having a hierarchy structures in which all the ADRs are grouped in System Organ Class (SOC) by type and etiology. The maximum precision level is defined by the preferred term, which we used for the selection of our cases. Vaccines were excluded from this analysis. Only drugs reported as suspected or interacting were evaluated. Considering that more than one drug could be reported as suspected, we analyzed the reports by drug-reaction pairs and not by number of reports. We performed a duplicate check using a record-linkage strategy by grouping the overlapping records in 8 key fields: country-text, gender, age-reaction, re-outcome, preferred-base name, reported-term, onset date, and start date.

84 The records having 7 out of 8 overlapping information and a single missing data in the
85 relevant key fields were considered as duplicates. We selected the drug – DIC pairs and
86 we evaluated the disproportionality of these pairs compared to the others in the
87 database. This analysis was performed using the Reporting Odds Ratio (ROR) with 95%
88 confidence interval and $p \text{ value} \leq 0.05$. This is a quantitative approach based on
89 frequency analysis of 2 x 2 contingency table, developed for evaluating drug – reaction
90 frequency compared to reference distributions of other ones from the whole database
91 [8]. If $ROR < 1$, it is assumed that we are in absence of disproportionality and the
92 distribution of reported adverse events is the same across drugs [9]; conversely, if ROR
93 is > 1 there is an increased frequency for the drug – reaction pair considered. Only drugs
94 with the lower bound of the 95% CI > 1 were considered as related with the ADR
95 considered. For each drug with a statistically significant ROR ($ROR > 1$, $p \text{ value} \leq 0.05$,
96 lower bound 95% CI > 1), we verified if disseminated intravascular coagulation was
97 reported in the Summary of Product Characteristics (SPCs) of the corresponding
98 medicinal products, made available by the Italian Medicine Agency (AIFA), the
99 European Medicines Agency (EMA) and the Electronic Medicines Compendium
100 (eMC).

Results

Descriptive analysis

Analyzing reports from 1968 to December 2015 in Vigibase, we collected 4,771 Individual Case Safety Report (ICSR) referred to disseminated intravascular coagulation. After the exclusion of duplicates, 4,653 reports remained for the analysis (*Figure 1*). Focusing on these reports, 42.7% were related to 18 - 64 years patients, 29.9% to ≥ 65 years and 8.5% to 0 - 17 years. In about 19% of the cases, age was not available. Negligible difference emerged between females and males (51.2% and 45.1% respectively), while information about gender was not available in 3.7% of the reports. *Table 1* shows reports classified according to age class, number of reports (N) and gender for each class. About “seriousness” criteria, we applied ICSRs standards and out of 4653 reports, 75.9% was classified as serious, while only 1.25% was not serious. Seriousness was missing in 1066 (22.9%) reports. The highest number of serious cases on the total amount of reports per class was detected in ≥ 65 years class (1104 out of 1391, 79.4%). Considering “serious” cases, 1938 (54.9%) had a fatal outcome. Of these, 38.4% (697 of 1938) occurred in 18 – 64 years class, 36.0% (697 of 1938) in elderly and 7.6% (147 of 1938) in 0 – 17 years class. The mortality rate, calculated on the total number of reports per age class were: 36.8% in the 0 – 17 years class, 37.4% in the 18 – 64 years class and 50.1% in the elderly. *Table 1* also shows “seriousness” classification and fatal outcome for each class.

Disproportionality analysis

Out of the total number of reports collected in Vigibase, 4,653 reports were selected applying exclusions criteria (e.g.: all duplicates with same information such as origin, gender, age or suspected drugs). In these reports, 1,111 drugs were reported as

associated with DIC. Among these, 407 drugs have been excluded because reported
 DIC only once and this was considered not enough to generate an alarm signal. The 704
 remaining drugs were reported as suspected/interacting in more than one report related
 to DIC. The top five drugs reported of 704 remaining were: heparin (184 reports),
 methotrexate (143 reports), paracetamol (117 reports), vincristine (110 reports) and
 cytarabine (108 reports). Eighty-eight drugs were statistically associated with DIC
 (ROR > 1, 95% confidence interval and p value ≤ 0.05). Among these, the most
 frequently reported was paracetamol (117 reports), ROR [1.21 (95% CI 1.00 – 1.48)],
 followed by dabigatran (94 reports) ROR [1.34 (1.08 – 1.67)], oxaliplatin and
 bevacizumab both with 75 reports, ROR [1.77(1.38 – 2.27)] and ROR [2.02 (1.57 –
 2.61)] respectively. According to the ATC II level classification, the highest number of
 drugs reported belong to antineoplastic agents (18 drugs), antithrombotic agents (12
 drugs) and antibacterials for systemic use (10 drugs). Reports of antineoplastic agents
 (L01, 593 reports) include oxaliplatin, bevacizumab, sunitinib ROR [1.58 (1.22 – 2.06)],
 cisplatin ROR [1.72 (1.32 – 2.25)] and other 14 drugs; only for sunitinib DIC was an
 ADR reported in SPC. As far as antithrombotic agents (B01, 290 reports), significant
 RORs were observed for dabigatran, drotrecogin alfa ROR [2.05 (1.58 – 2.66)],
 clopidogrel ROR [1.70 (1.24 – 2.32)], abiciximab ROR [2.21(1.35 – 3.62)] and other 8
 drugs. For all these drugs, DIC was not reported in the SPCs. Other two classes with
 high reporting frequency were N02 - analgesics (149 reports) and J01 - antibacterials for
 systemic use (102 reports). *Table 2* shows the 88 drugs and the relative RORs; only 10
 out of 88 have DIC listed in their SPCs: sunitinib, tegafur/gimeracil/oteracil, heribulin,
 eptacog alfa, hetastarch, edaravone, rifampicin, quinine, acetylsalicylic acid and
 dinoprostone.

Discussion

To the best of our knowledge, this is the first study concerning drug-induced DIC based on data of spontaneous reporting collected from Vigibase. DIC is a rare syndrome and it is even more infrequent as an ADR and evidences in literature are poor. Anyway, great attention should be paid to this ADR because in the elderly, half of the reports of adverse reactions, had a fatal outcome. The high DIC mortality rate strengthens the need to understand all the possible causes and to identify all the drugs associated to it, in order to diagnose the ADR precociously. Overall, 88 drugs were statistically associated with DIC, a great number if we consider that only for 10 of them the ADR is reported in the corresponding SPC. For example, paracetamol shows a $ROR > 1$ in our analysis, although the lower limit of the confidence interval was $CI_{low95\%} = 1.00$. The association paracetamol-DIC has been previously highlight by the Italian Medicine Agency (AIFA) in three case reports of the December 2006 bulletin [10]. Paracetamol is one of the most used drug worldwide, so it would be important to define clearly its safety profile. Also oxaliplatin and bevacizumab were between the most reported drugs. The class of antineoplastic agents deserves attention based on the several reports identified (593). A statistically significant disproportionality has been obtained with many drugs of the class such as oxaliplatin, bevacizumab, fluorouracil, irinotecan and cetuximab. Literature provides evidences regarding a case report of DIC during third-line treatment with cetuximab plus irinotecan, following 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab and 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) plus bevacizumab [11] that is in accordance to our data. To note that DIC could be also caused by tumor as well, both solid tumors and hematologic cancers [4], and this makes the causality assessment complicated. Another high reported class were antithrombotic/anticoagulant drugs (290 reports), in which we find a signal from the association dabigatran – DIC. A recent published article concerning efficacy and safety

of direct oral anticoagulants is in agreement with our data: the association between dabigatran and DIC has been classified as statistically significant and the author explained that it was the suspected drug in about 90% of cases [8]. In dabigatran SPC it is reported that it extends both prothrombin time and activated partial thromboplastin time, as it happens in essential laboratory tests for DIC diagnosis. None report was retrieved for other anticoagulants of the class such as rivaroxaban and apixaban. This could be due to the higher use of dabigatran in clinical practice [12,13]. The third most reported class was antibacterials agents for systemic use, but few evidences are present in literature. In general, all these three classes are also the most used drugs for the treatment of pathological conditions associated with the development of DIC. This underlines the need to carry out further studies to better understand the etiology and the possible causal association with the administration of the aforementioned drugs. Anyway, confirmations to the data of our study is given from the 10 drugs resulted to be associated with DIC, for which it is an ADR reported in the SPCs and confirmed by findings in the literature. These include sunitinib, the combination tegafur/gimeracil/oteracil, eribulin, hetastarch, rifampin, quinine, acetylsalicylic acid, dinoprostone and edaravone. Overall, considering the high mortality rate, the large number of reports retrieved and the confirmations deriving from drugs reports for which DIC is already known, we can say that it would be appropriate to carry out further analysis in order to obtain more confirmations to these possible associations identified. Only with further studies, it will be possible to guarantee the updating of the SPCs and ensure safer use of these drugs. Between the limitations of our study, stimulating reporting or under reporting represents bias in the analysis. Underreporting widespread and it is estimated that only the 10% of ADRs occurring in everyday clinical practice are actually reported [14]. DIC underreporting could also be linked to doubts about the causality role of drugs involved. In addition, clinical information in spontaneous reports

are limited and not completed, for example co-morbidities could not be reported. DIC could also be caused by trauma, sepsis or malignancy so it is important to know every clinical information about patients in order to assess the right causality. Furthermore, the preferred term “disseminated intravascular coagulation” is highly specific and not always clinicians should use this term for report DIC in ADR reports but may use other generic terms such as coagulopathy or hematological disorders, which cause a bias in entire following analysis. Inaccuracies in the initial evaluation of clinical condition could lead to an incorrect assessment. Lastly ROR computing does not allow to quantify the actual risk of an ADR but only suggests a statistically significant association between events and drugs. The indication of a statistically significant association must be confirmed and deepened by other epidemiological studies. Nevertheless, the spontaneous reporting remains one of the simplest, low cost and essential methods for identifying ADR during post-marketing surveillance.

Conclusion

The results of our analysis highlight that a considerable number of drugs widely used in clinical practice may be associated with the potential occurrence of DIC. For many of these, the ADR is not reported in the SPC and this may be a further obstacle for the identification. The high number of drugs involved, the few evidences in literature and the great number of fatal outcome underline the importance of evaluate this condition such as an ADR that might occur during therapy. Our study provides valuable data for further analysis and clinicians should be aware of the importance to identify and report every case of suspected drug – related DIC. Studies based on spontaneous reporting, even with limitations, allow to detected ADRs after marketing authorization and improve knowledge on the safety profile of many drugs.

Author contributions: Conceptualization, GB, AV and DM; Data curation, MM; Formal analysis, GB, AV, MM, DM; Investigation, GB, DM; Methodology, GB, DM, MM; Supervision, AV; Validation, MM; Writing – original draft, GB, DM; Writing – review & editing, GB, AV, MM, DM.

Conflict of interest: All the Authors declare that they have no conflict of interest. This manuscript has no founding source.

Compliance with Ethical Standards: The manuscript does not contain clinical studies or patient data. For this type of study, formal consent is not required.

References

1. Brunton L, Chabner B.A, (2012) Knollman B, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed., McGraw-Hill Education / Medical.
2. Gando S, Otomo Y. (2015) Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. *Critical Care*; <https://doi.org/10.1186/s13054-015-0735-x>
3. Wada H, Matsumoto T, Yamashita Y. (2014) Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. *J Intensive Care*; <https://doi.org/10.1186/2052-0492-2-15>
4. Levi M, Ten Cate H. (1999) Disseminated Intravascular Coagulation. *N Engl J Med*; <https://doi.org/10.1056/NEJM199908193410807>
5. NW Liles, EE. Page, AL Liles et al. (2016) Diversity and severity of adverse reactions to quinine: A systematic review. *Am. J. Hematol.* <https://doi.org/10.1002/ajh.24314>
6. SR White. (2002) Amphetamine toxicity. *Semin Respir Crit Care Med*. DOI: 10.1055/s-2002-20586

7. The WHO Programme for International Drug Monitoring. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/ [Accessed 22/11/2019]
8. Monaco L, Biagi C, Conti V, et al. (2017) Safety profile of the direct oral anticoagulants: an analysis of WHO database of adverse drug reactions. *Br J Clin Pharmacol*. <https://doi.org/10.1111/bcp.13234>
9. Shibata, A., Hauben, M. (2011) Pharmacovigilance, signal detection and signal intelligence overview. In *Information Fusion (FUSION)*, Proceedings of the 14th International Conference, Chicago, IL, USA, July 5–8 2011; IEEE: New York, NY, USA, 2011; pp. 1–7.
10. Italian Medicine Agency (2016) Report available at: http://www.agenziafarmaco.gov.it/wscs_render_attachment_by_id/111.28397.11666135094017ecc.pdf [Accessed 22/01/2018]
11. Mizota A, Shitara K, Kondo C, et al. (2011) A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab. *Int J Clin Oncol*. <https://doi.org/10.1007/s10147-011-0242-2>
12. J Marler, JB Usery, S Nolan et al. “Antithrombotic Usage Patterns in the Era of New Oral Anticoagulant Options for Atrial Fibrillation” *Hosp Pharm*. 2016 51(7): 564–571 doi: 10.1310/hpj5107-564
13. L Staerk, EL Fosbøl, K Gadsbøll et al. (2016) Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. *Sci Rep*. Aug 11;6:31477. doi: 10.1038/srep31477.
14. Biagi C, Montanaro N, Buccellato E, et al. (2013) Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia–Romagna region). *Eur J Clin Pharmacol*. 2013 <https://doi.org/10.1007/s00228-012-1321-7>

Figure Legend:

- **Figure 1: Flowchart of the Individual Case Safety Reports selection**